DexCom (NASDAQ:DXCM) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday.

According to Zacks, “Over the past year, DexCom has underperformed the broader industry in terms of price. Cutthroat competition in the market for blood & glucose monitoring devices is a headwind. We believe the company’s margins will continue to be under pressure in the coming quarters, owing to high product development costs and rising expenditures on research & development. Lower expected margins on transmitter sales is also a cause of concern. However, the company is well positioned in the MedTech space, courtesy of solid contribution from Sensor revenues, Transmitter revenues and Receiver revenues in the last few quarters. The glucose monitoring market represents significant commercial opportunity for DexCom. The company’s solid foothold in the international markets, especially Germany, broad spectrum of products and strategic collaborations, are promising.”

DXCM has been the subject of several other research reports. TheStreet cut DexCom from a “c-” rating to a “d+” rating in a research note on Wednesday, October 25th. BidaskClub cut DexCom from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 22nd. Oppenheimer set a $67.00 target price on DexCom and gave the company a “buy” rating in a research note on Monday. ValuEngine upgraded DexCom from a “sell” rating to a “hold” rating in a research report on Monday, November 6th. Finally, Morgan Stanley decreased their price target on DexCom from $72.00 to $52.00 and set a “neutral” rating for the company in a research report on Friday, November 3rd. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $67.44.

Shares of DexCom (DXCM) traded up $0.34 during mid-day trading on Tuesday, reaching $54.69. The company had a trading volume of 694,700 shares, compared to its average volume of 1,376,817. DexCom has a fifty-two week low of $42.62 and a fifty-two week high of $86.32. The company has a market capitalization of $4,750.00, a PE ratio of -95.95 and a beta of 0.21. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50.

In related news, CEO Kevin R. Sayer sold 12,000 shares of the stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $55.00, for a total value of $660,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Richard Doubleday sold 1,635 shares of the stock in a transaction dated Friday, November 24th. The stock was sold at an average price of $55.53, for a total value of $90,791.55. Following the completion of the sale, the executive vice president now directly owns 65,049 shares of the company’s stock, valued at $3,612,170.97. The disclosure for this sale can be found here. Over the last three months, insiders sold 48,140 shares of company stock valued at $2,743,281. Company insiders own 1.70% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. State Street Corp raised its stake in shares of DexCom by 2.5% during the 2nd quarter. State Street Corp now owns 1,549,843 shares of the medical device company’s stock worth $113,374,000 after purchasing an additional 37,581 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of DexCom by 3.2% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 265,019 shares of the medical device company’s stock worth $12,967,000 after purchasing an additional 8,171 shares in the last quarter. Peregrine Capital Management LLC raised its stake in shares of DexCom by 24.5% during the 3rd quarter. Peregrine Capital Management LLC now owns 395,455 shares of the medical device company’s stock worth $19,348,000 after purchasing an additional 77,868 shares in the last quarter. Tirschwell & Loewy Inc. raised its stake in shares of DexCom by 1.1% during the 3rd quarter. Tirschwell & Loewy Inc. now owns 270,595 shares of the medical device company’s stock worth $13,239,000 after purchasing an additional 2,900 shares in the last quarter. Finally, Swiss National Bank raised its stake in shares of DexCom by 3.4% during the 3rd quarter. Swiss National Bank now owns 318,400 shares of the medical device company’s stock worth $15,578,000 after purchasing an additional 10,500 shares in the last quarter.

WARNING: “Zacks Investment Research Lowers DexCom (DXCM) to Sell” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://theolympiareport.com/2018/02/13/zacks-investment-research-lowers-dexcom-dxcm-to-sell.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Get a free copy of the Zacks research report on DexCom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.